Lucid Is Changing the Conversation Around GERD & Esophageal Cancer

Dr. Lishan Aklog stops by Let’s Talk Medtech to discuss the impact of Lucid Diagnostics and being CEO of two companies during a pandemic.

Omar Ford

January 14, 2022

1 Min Read
Courtesy of Lucid Diagnostics and PavMed

Hear Lishan Aklog speak at IM Engineering South on Tuesday, June 14, 2022.

Dr. Lishan Aklog wears multiple hats. He's the CEO of both PavMed and Lucid Diagnostics. Being a CEO of two companies during the pandemic can be tough at times, but Dr. Aklog's biggest challenge is getting out the awareness of how some instances of GERD can lead to Esophageal Cancer.

Dr. Aklog stops by for an amazing conversation on how Lucid Diagnostics is making an impact in the detection of Esophageal Cancer.

The company has the EsoCheck, an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in a less than five-minute office. The samples are then checked with the EsoGuard test.

PavMed announced it was spinning out Lucid in February of 2021. Lucid was formed in May 2018 as a subsidiary of our parent company, PAVmed to license the technologies underlying EsoGuard and EsoCheck from Case Western Reserve University. 

Check out the conversation with Dr. Aklog on Let's Talk Medtech below. 


About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like